行情

ACRX

ACRX

AcelRx制药
NASDAQ

实时行情|Nasdaq Last Sale

1.280
-0.010
-0.78%
盘后: 1.250 -0.03 -2.34% 19:35 04/07 EDT
开盘
1.300
昨收
1.290
最高
1.370
最低
1.220
成交量
136.05万
成交额
--
52周最高
4.000
52周最低
0.7014
市值
1.03亿
市盈率(TTM)
-1.9039
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACRX价格均价为5.80,最高价位9.00,最低价为1.000。

EPS

ACRX 新闻

更多
  • Facebook面向情侣发布新聊天应用 可记录爱情时间线
  • 新浪科技 · 38分钟前
  • Twitter创始人宣布捐献10亿美元抗击新冠病毒
  • 新浪科技 · 1小时前
  • 特朗普:美国将研究暂扣为世卫组织提供的资金
  • 新浪美股 · 1小时前
  • 隔夜要闻:道指回吐逾900点涨幅 美油下挫逾9%
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
-2.89%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

ACRX 简况

AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.
展开

微牛提供AcelRx Pharmaceuticals Inc(NASDAQ-ACRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACRX股票新闻,以帮助您做出投资决策。